title: Short-term effects of recombinant human insulin-like growth factor I on bone turnover in normal women.
abstract: Because insulin-like growth factor I (IGF-I) is a potent stimulator of osteoblast proliferation, it has potential in the treatment of osteoporosis. However, IGF-I affects multiple organ systems, and it is unclear whether treatment can stimulate bone formation without producing unacceptable side effects. Therefore, we evaluated the effects of treatment with recombinant human IGF-I in 18 postmenopausal women who received various dosages (30, 60, 120, or 180 micrograms/kg.day) by sc injections for 6 days. Serum IGF-I concentrations increased by 2- to 4-fold during treatment. There were dose-dependent increases in serum type I procollagen carboxyl-terminal propeptide concentration (r = 0.85, P < 0.001), an index of collagen synthesis, and of urinary excretion of deoxypyridinoline (r = 0.75, P = 0.001), an index of bone collagen breakdown. At the two higher dosages, recombinant human IGF-I caused orthostatic hypotension, sinus tachycardia, bilateral parotid discomfort, weight gain, and edema in some women. Hypoglycemia did not occur. However, treatment at the 2 lower dosages increased serum type I procollagen carboxyl-terminal propeptide significantly and produced minimal or no side effects. Long-term studies on the effects and the safety of low dosage recombinant human IGF-I on bone mass should now be undertaken in osteoporotic women.
authors.affiliation: Division of Endocrinology and Metabolism, Mayo Clinic, Rochester, Minnesota 55905.
authors.forename: P R
authors.initials: PR
authors.lastname: Ebeling
authors.forename: J D
authors.initials: JD
authors.lastname: Jones
authors.forename: W M
authors.initials: WM
authors.lastname: O'Fallon
authors.forename: C H
authors.initials: CH
authors.lastname: Janes
authors.forename: B L
authors.initials: BL
authors.lastname: Riggs
mesh_terms: D000368:Aged; D000596:Amino Acids / Q000652:urine; D001842:Bone and Bones / Q000187:drug effects* / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000009:adverse effects / Q000494:pharmacology*; D008875:Middle Aged; D010446:Peptide Fragments / Q000097:blood; D011347:Procollagen / Q000097:blood; D011994:Recombinant Proteins; D012016:Reference Values; D013997:Time Factors
chemical_list: D000596:Amino Acids; D010446:Peptide Fragments; D011347:Procollagen; D011994:Recombinant Proteins; C042813:procollagen type I carboxy terminal peptide; D007334:Insulin-Like Growth Factor I; C036020:deoxypyridinoline